RxDoctor Payments Data

Barbara Wiles

Family · Mesa, AZNPI 1376707406

Payments from drug & device makers

$2,030in general payments, 2019–2025

Across 19 payments — averaging $106.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$375
  • Edwards Lifesciences$275
  • E.r. Squibb & Sons, L.L.C.$216
  • Atricure, Inc.$166
  • Heartflow, Inc.$162
  • Sanofi-aventis U.S. LLC$150
  • plus $687 from 6 others

What the payments were for

  • Food & beverage$2,029100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,030 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$37,649
Medicare patients
79
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$58,578
EntrestoSacubitril/Valsartan35$22,306
XareltoRivaroxaban14$9,298
Isosorbide Mononitrate ErIsosorbide Mononitrate200$3,798
Hydralazine Hcl165$2,828
Amlodipine Besylate197$2,606
Torsemide166$2,447
Atorvastatin Calcium153$2,412
Pravastatin Sodium105$1,901
Lisinopril132$1,866
Carvedilol97$1,833
Midodrine Hcl26$1,803
Metoprolol Succinate102$1,786
Losartan Potassium96$1,408
Metoprolol Tartrate101$1,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$111$22,30635 claims
Johnson & JohnsonXarelto$118$9,29814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.

Other family in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →